Recombinant erIL-15 NK cells

Patent metadata

Field	Value
Publication number	US-12516093-B2
Application number	US-202217732190-A
Country	US
Kind code	B2
Filing date	Apr 28, 2022
Priority date	Mar 15, 2019
Publication date	Jan 6, 2026
Grant date	Jan 6, 2026

Abstract

Systems and methods are presented that provide for improved NK cell function. In preferred aspects, NK-92 cells express recombinant er/LSP-IL-15 to so render the NK-92 cells independent of exogenous cytokines and to provide extracellular immune stimulation.

First claim

What is claimed is:

1 . A method of treatment for cancer, the method comprising administering to a patient in need thereof a genetically modified NK cell comprising a recombinant nucleic acid that encodes erLSP-IL-15 according to SEQ ID NO:5.

2 . The method of claim 1 , wherein the NK cell is an NK-92 cell.

3 . The method of claim 1 , wherein the recombinant nucleic acid is a DNA.

4 . The method of claim 3 , wherein the recombinant nucleic acid is a linearized plasmid.

5 . The method of claim 3 , wherein the recombinant nucleic acid further comprises a second segment encoding CD16 or a high affinity CD16.

6 . The method of claim 5 , wherein the recombinant nucleic acid further comprises a third segment encoding a chimeric antigen receptor.

7 . The method of claim 6 , wherein the recombinant nucleic acid further comprises a fourth segment encoding a protein that interferes with checkpoint inhibition, that provides immune stimulation, a protein that binds/inhibits a cytokine involved with immune suppression, and/or a IL-15 receptor alpha chain.

8 . The method of claim 1 , wherein the recombinant nucleic acid comprises a promotor having a sufficient strength to drive expression of the erLSP-IL-15 in an amount sufficient to (a) render the modified NK cell independent from exogenous cytokines, and to (b) allow for stimulation/activation of other immune competent cells that are in proximity to the modified NK cell.

9 . The method of claim 1 , further comprising administering an antibody coupled to the NK cell via CD16, wherein the coupling occurs prior to administration.

10 . The method of claim 1 , wherein between 5×10 7 and 5×10 10 cells are administered.

11 . The method of claim 1 , wherein between 7×10 8 and 7×10 9 cells are administered.

12 . The method of claim 1 , wherein 2×10 9 cells are administered.

13 . The method claim 1 , wherein the cells are administered intravenously.

14 . The method of claim 1 , wherein the cells are co-administered with one or more therapeutic agents comprising a chemotherapy, an immune stimulant, a cancer vaccine, and/or tumor-targeted IL-12.

15 . The method of claim 14 , wherein the cells are co-administered with Alt-803.

Assignees

• Nantcell Inc
• Nantbio Inc
• Immunitybio Inc

Inventors

• Soon-Shiong Patrick
• Rabizadeh Shahrooz
• Niazi Kayvan
• Klingemann Hans G

Classifications

• A61K40/4221

  CD20 · CPC title

• A61K40/4211

  CD19 or B4 · CPC title

• A61K40/421

  Immunoglobulin superfamily · CPC title

• A61K40/35

  Cytokines · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title